1. Graeff H, Harbeck N, Pache L, Wilhelm O, Janicke F, Schmitt M. Prognostic impact and clinical relevance of tumor-associated proteases in breast cancer. Fibrinolysis 1992; 6 [Suppl 4]: 45.
2. Duffy MJ. Urokinase-type plasminogen activator and malignancy. Fibrinolysis 1993; 7: 295.
3. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K, Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-l in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53:2513.
4. Mulcahy HF, Duffy MJ, Gibbons D, McCarthy P, Parfray NA, O'Donoghue UP, Sheahan K. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994: 344:583.
5. Ganesh S, Sier CFM, Griffioen G, Vloedgraven HJM, Boer A de, Welvaart K, Velde CJH van de; Krieken JHJM van; Verheijen JH, Lamers CBHW, Verspaget HW. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994; 54: 4065.